Background: Loss of circadian rhythms and reduced concentrations of endogenous melatonin are common in critically ill patients. After exogenous administration, supra-physiological concentrations in serum are only ephemeral, which may explain the absence of significant therapeutic effect on sleep. The aim of this study is to describe the pharmacokinetics of enteral melatonin in critically ill patients administered in a novel regimen aiming to simulate endogenous release.
Methods: Thirteen patients in the recovery phase of critical illness were randomised to receive enteral melatonin or placebo. In the melatonin group, a total of 6 mg was administered as solution through their feeding tube, commencing with a 3 mg loading dose at 9 pm and six subsequent 0.5 mg doses hourly. The placebo was administered using a similar regimen. Serial blood samples were taken and measured using a validated chromatographic method. The concentration-time data for serum melatonin concentrations were described using non-linear mixed-effects modelling.
Results: The observed concentrations in the melatonin patients were significantly higher than that observed in the placebo patients. The concentrations in the patients administered melatonin were also higher than endogenous melatonin concentrations previously reported in non-critically ill patients. The patients administered melatonin had a mean clearance, volume of distribution and absorption rate constant of melatonin was 55.2 L/h, 767 L and 0.76 h–1, respectively.
Conclusions: Exogenous administration of melatonin with a loading dose of 3 mg followed by an hourly dose of 0.5 mg demonstrates good oral bioavailability and results in supra-physiological and sustained concentrations of serum melatonin during 12 h overnight.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This work was supported by the Royal Brisbane and Women’s Hospital, Research Foundation project grant 2011. Jason Roberts is supported by a Career Development Fellowship from the National Health and Medical Research Council of Australia (APP1048652).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Bellapart J, Boots R. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth 2012;108:572–80. Search in Google Scholar
2. Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, et al. Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiol Int 2000;17:71–6. Search in Google Scholar
3. Ibrahim MG, Bellomo R, Hart GK, Norman TR, Goldsmith D, Bates S, et al. A double-blind placebo-controlled randomised pilot study of nocturnal melatonin in tracheostomised patients. Crit Care Resusc 2006;8:187–91. Search in Google Scholar
4. Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit Care 2008;12:R52. Search in Google Scholar
5. Mistraletti G,Umbrello M, Sabbatini G, Miori S, Taverna M, Cerri B, et al. Melatonin reduces the need for sedation in ICU patients. A randomized controlled trial. Minerva Anestesiol [Epub ahead of print 2015 May 13]. Search in Google Scholar
6. Mistraletti G, Mantovani ES, Cadringher P, Cerri B, Corbella D, Umbrello M, et al. Enteral vs. intravenous ICU sedation management: study protocol for a randomized controlled trial. Trials 2013;14:92. Search in Google Scholar
7. Arendt J. Importance and relevance of melatonin to human biological rhythms. J Neuroendocrinol 2003;15:427–31. Search in Google Scholar
8. Zaidan R, Geoffriau M, Brun J, Tailard J, Bureau C, Chazot G, et al. Melatonin is able to influence its secretion in humans: description of a phase-response curve. Neuroendocrinology 1994;60:105–12. Search in Google Scholar
9. Mallo C, Zaidan R, Galy G, Vermeulen E, Brun J, Chazot G, et al. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol 1990;38:297–301. Search in Google Scholar
10. Bourne RS, Mills GH. Melatonin: possible implications for the postoperative and critically ill patient. Intensive Care Med 2006;32:371–9. Search in Google Scholar
11. Paul T, Lemmer B. Disturbance of circadian rhythms in analgosedated intensive care unit patients with and without craniocerebral injury. Chronobiol Int 2007;24:45–61. Search in Google Scholar
12. Nishimura S, Fujino Y, Shimaoka M, Hagihira S, Taenaka N, Yoshiya I. Circadian secretion patterns of melatonin after major surgery. J Pineal Res 1998;25:73–7. Search in Google Scholar
13. Frisk U, Olsson J, Nylen P, Hahn RG. Low melatonin excretion during mechanical ventilation in the intensive care unit. Clin Sci (Lond) 2004;107:47–53. Search in Google Scholar
14. Mundigler G, Delle-Karth G, Koreny M, Zehetgruber M, Steindl-Munda P, Marktl W, et al. Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med 2002;30:536–40. Search in Google Scholar
15. Olofsson K, Alling C, Lundberg D, Malmros C. Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients. Acta Anaesthesiol Scand 2004;48:679–84. Search in Google Scholar
16. Miyazaki T, Kuwano H, Kato H, Ando H, Kimura H, Inose T, et al. Correlation between serum melatonin circadian rhythm and intensive care unit psychosis after thoracic esophagectomy. Surgery 2003;133:662–8. Search in Google Scholar
17. Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, et al. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res 2010;48:142–7. Search in Google Scholar
18. Arendt J. Melatonin: characteristics, concerns, and prospects. J Biol Rhythms 2005;20:291–303. Search in Google Scholar
19. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982;8:195–222. Search in Google Scholar
20. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999;59:19–29. Search in Google Scholar
21. Lane EA, Moss HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab 1985;61:1214–6. Search in Google Scholar
22. Sharma M, Palacios-Bois J, Schwartz G, Iskandar H, Thakur M, Quirion R, et al. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 1989;25:305–19. Search in Google Scholar
23. Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, et al. Patients in the intensive care unit suffer from severe lack of sleep associated with loss of normal melatonin secretion pattern. Am J Med Sci 1999;317:278–81. Search in Google Scholar
©2016 by De Gruyter